Reading a barrel: the graduation that is not the one you think
Dead space in the needle hub is a real and calculable loss, and it matters more at small volumes than anybody expects.
Dosing
Page 7 of 31 of this archive, newest first.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new South Africa guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Hydration, protein and the two failures that compound each other
The intervention with the clearest evidence is the one nobody frames as an intervention: adjusting the dose.
What happens when the drug is taken away: three randomised answers
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Adverse events by dose, adverse events by week
Almost every figure in circulation about tolerability comes from six publications. This is what they say.
Escalating past the approved maximum, examined honestly
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
Australia pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
What happens when the drug is taken away: three randomised answers
What was withdrawn, from whom, after how long, and what was measured afterwards.
The ceiling is a tolerability finding, not an efficacy one
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
Reading the receptor: what distinguishes cagrilintide from survodutide at the molecular level
A tour of what happens in the thirty seconds after binding, and why it matters at week thirty.
Spain pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Holding a dose is a decision, not a failure
A dose held long enough stops being a pause and becomes a maintenance decision. That transition is rarely made explicitly.
What actually helps, ranked by evidence
We separate what is supported, what is reasonable, and what is folklore, and we do not pretend the boundaries are crisp.
The intramuscular injection nobody intended
Longer needles reach muscle in lean limbs, and intramuscular delivery of a long-acting depot changes absorption in ways nobody wants.
What actually helps, ranked by evidence
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Mexico pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The United Arab Emirates pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.